The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

lunguard.com

Stage

Other Investors | Alive

About LunGuard

LunGuard, founded in 2009, has developed a reflux prevention system (RPS) – a unique and proprietary solution for better and safer care of nasogastric (NG) tube fed patients in both critical care settings (e.g., ICU, early preterm, OR) and in short/long-term care settings (e.g., home care/nursing home patients with cognitive impairments).

LunGuard Headquarter Location

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

LunGuard Patents

LunGuard has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/7/2013

12/26/2017

Digestive system, Fluid dynamics, Esophagus disorders, Medical equipment, ATC codes

Grant

Application Date

7/7/2013

Grant Date

12/26/2017

Title

Related Topics

Digestive system, Fluid dynamics, Esophagus disorders, Medical equipment, ATC codes

Status

Grant

LunGuard Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LunGuard Rank

  • What is LunGuard's latest funding round?

    LunGuard's latest funding round is Other Investors.

  • Who are the investors of LunGuard?

    Investors of LunGuard include Previz Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.